Tag Archives: pharmacogenomics

Tradable Bottom In With Biotech But Don’t Go Crazy

Large Caps Are Recovering But Follow Q1 Earnings Closely Fidelity Select Biotech FBIOX( $176 ) must hold $172 for new buys. Healthcare sector XLV ($56.94)  lagging industrials and energy. April 15 Low Must Hold IBB ($207.70) Our top picks that are off 5 day bottom and higher: ABBV ALKS ALXN, BIIB, GILD. Even laggard Celgene […]

Leave a comment Continue Reading →

Biotech Rout Not Surprising: Surveying The Damage

Top Ten Reasons For Biotech Correction NASDAQ at 4022,IBB at 221 A Sentiment Driven Market We have been writing about the bull market in biotech stocks since its inception in March 2009 when quality companies were advancing their pipelines and new products in immunology, oncology and infectious disease were being launched. The life science sector […]

Leave a comment Continue Reading →

Seeking A Technical Bottom For Biotech Stocks….. Update 4/9 Rally

NASDAQ Up 0.37% to 4133 Green screen alert with large cap biotechs. Time to cover hedges. Alexion (ALXN) up 2.23% Biogen (BIIB) Up 2.4% Celgene (CELG) up 3.61% Clovis Oncology (CLVS) up 2.85% Gilead (GILD) up 1.35% IBB up 1.96% Regeneron (REGN) up 3.99% Key Trends To Watch: April Update After Correction We provided a […]

Leave a comment Continue Reading →

Rayno Biopharmaceutical Stocks Q1 2014 Performance

Rayno Biopharmaceutical Portfolio 3/31/14 Most of our biotech picks did well in a tough quarter that went through a severe correction in early February and again in late March. Many small and mid-cap momentum stocks were crushed but indices (FBT,IBB) overall held the early February technical levels. Use the two ETFs and FBIOX for re-balancing […]

Comments Off Continue Reading →

Rayno Life Science Stocks Rally: Green Screen… IBB UP 2.5% Update

Update 3/19/14 Trading is mixed near flat line. Cramer to pump Seattle Genetics (SGEN ($53.51 flat) today; on our focus list since’09 at $9.50. Exact Sciences (EXAS) up ~3% on data release for Cologuard compared to FIT. Sensitivity of 92% with colorectal cancer and 42% with pre-cancerous lesions. (See detailed data). 2015 revenue forecasts from […]

Comments Off Continue Reading →

A Good Week For Rayno Life Science Stocks: AMRI, CBST, ILMN, RHHBY

Rayno Life Science Movers -Diagnostics Review Next Week Despite some choppiness in biotech trading this week many of our stocks did well. I won’t go into some of the unusual volatility in other small and mid-caps lately  but that is part of the reason for my “bubble” article. There is also a lot of focus […]

Comments Off Continue Reading →